NASDAQ:LUNG - Nasdaq - US7458481014 - Common Stock - Currency: USD
NASDAQ:LUNG (4/24/2025, 1:22:57 PM)
5.19
+0.2 (+4.01%)
The current stock price of LUNG is 5.19 USD. In the past month the price decreased by -27.47%. In the past year, price decreased by -31.46%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 27.07 | 224.40B | ||
ISRG | INTUITIVE SURGICAL INC | 66.48 | 181.97B | ||
BSX | BOSTON SCIENTIFIC CORP | 37.41 | 149.42B | ||
SYK | STRYKER CORP | 29.5 | 137.27B | ||
MDT | MEDTRONIC PLC | 15.73 | 107.72B | ||
BDX | BECTON DICKINSON AND CO | 14.64 | 58.49B | ||
EW | EDWARDS LIFESCIENCES CORP | 28.82 | 44.05B | ||
IDXX | IDEXX LABORATORIES INC | 38.86 | 35.43B | ||
RMD | RESMED INC | 26.38 | 35.18B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 14.75 | 30.33B | ||
DXCM | DEXCOM INC | 42.58 | 27.55B | ||
PHG | KONINKLIJKE PHILIPS NVR- NY | 15.56 | 23.10B |
Pulmonx Corp. is a medical technology company, which engages in the provision of interventional pulmonology, planning tools and treatments for obstructive lung diseases. The company is headquartered in Redwood City, California and currently employs 291 full-time employees. The company went IPO on 2020-10-01. The firm provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. Its solutions, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System) and the StratX Lung Analysis Platform (StratX Platform), is designed to treat severe emphysema patients. The StratX Platform is a cloud-based quantitative CT analysis service that offers physicians with a report that is designed for its solution, which includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation and has been validated in multiple randomized controlled clinical trials.
PULMONX CORP
700 Chesapeake Dr
Redwood City CALIFORNIA 94063 US
CEO: Glendon E. French
Employees: 279
Company Website: https://pulmonx.com/
Investor Relations: https://investors.pulmonx.com/
Phone: 16509342600
The current stock price of LUNG is 5.19 USD. The price increased by 4.01% in the last trading session.
The exchange symbol of PULMONX CORP is LUNG and it is listed on the Nasdaq exchange.
LUNG stock is listed on the Nasdaq exchange.
13 analysts have analysed LUNG and the average price target is 12.68 USD. This implies a price increase of 144.26% is expected in the next year compared to the current price of 5.19. Check the PULMONX CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
PULMONX CORP (LUNG) has a market capitalization of 208.90M USD. This makes LUNG a Micro Cap stock.
PULMONX CORP (LUNG) currently has 279 employees.
PULMONX CORP (LUNG) has a resistance level at 5.74. Check the full technical report for a detailed analysis of LUNG support and resistance levels.
The Revenue of PULMONX CORP (LUNG) is expected to grow by 17.73% in the next year. Check the estimates tab for more information on the LUNG EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
LUNG does not pay a dividend.
PULMONX CORP (LUNG) will report earnings on 2025-04-30, after the market close.
PULMONX CORP (LUNG) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.4).
The outstanding short interest for PULMONX CORP (LUNG) is 3.3% of its float. Check the ownership tab for more information on the LUNG short interest.
ChartMill assigns a fundamental rating of 3 / 10 to LUNG. The financial health of LUNG is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months LUNG reported a non-GAAP Earnings per Share(EPS) of -1.4. The EPS increased by 12.5% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -34.63% | ||
ROE | -65.72% | ||
Debt/Equity | 0.4 |
ChartMill assigns a Buy % Consensus number of 80% to LUNG. The Buy consensus is the average rating of analysts ratings from 13 analysts.
For the next year, analysts expect an EPS growth of -12.67% and a revenue growth 17.73% for LUNG